For all the hullabaloo around M&A and licensing deals from China especially for antibody-drug conjugates (ADCs) of late, it’s easy to forget they have many inherent challenges in their design, which may lead quite a few to fall short down the road – despite high expectations.

Recently we asked ourselves is there a different way to go about killing cancer cells in late stage tumours more effectively?

In our latest company interview, the answer, at least in some instances could well be yes.

It’s also a lot of fun going off the reservation to hear more about next generation approaches from up and coming young biotech companies with well thought out approaches to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by